F2G
Financing Round
- Series D+
Round Led or Co-led By SymBiosis
F2G is a clinical-stage biopharmaceutical company developing orotomides, a novel class of antifungal agents. Its lead candidate, Olorofim, targets rare and resistant mold infections and has received multiple regulatory designations.
